Aspirin and Warfarin Comparison for Heart Failure Treatment

Pharmaceutical Information

Author: American Stroke Association
Published: 2012/02/06 - Updated: 2022/04/27
Contents: Summary - Introduction - Main - Related

Synopsis: Comparison of two anti-clotting medications warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm. To avoid bias, all patients had blood drawn on the same schedule and their pills adjusted so neither the patients nor their treating physicians knew which regimen they were taking. Death, ischemic stroke (caused by blockage of an artery feeding the brain) or intracerebral hemorrhage (bleeding inside the brain), which combined were the study's primary endpoint, occurred at 7.47 percent for patients assigned to warfarin and 7.93 percent for patients assigned to aspirin. The difference was not statistically significant.

Introduction

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin was similar to aspirin in preventing deaths and strokes in patients with heart failure with normal heart rhythm.

Main Digest

Although there was no difference for the overall study, there was greater benefit of warfarin among patients followed for four or more years. Bleeding episodes were more common with warfarin than aspirin, but dangerous bleeding in the brain occurred at low levels in both groups.

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin, and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

"Although there was a warfarin benefit for patients treated for four or more years, overall, warfarin, and aspirin were similar," said Shunichi Homma, M.D., lead author of the study and the Margaret Milliken Hatch Professor of Medicine at Columbia University in New York.

In the 11-country Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial, researchers followed 2,305 patients with heart failure and normal heart rhythm for up to six years (average 3.5 years). The patients were on average 61 years old, and the power of the heart's main pumping chamber, the left ventricle (left ventricular ejection fraction), was less than 35 percent (normal is 55 percent or higher).

Thirteen percent of the patients experienced a stroke or transient ischemic attack and were at heightened risk of recurrence. Patients with heart failure in general are at increased risk of death, blood clots and strokes.

Researchers randomly assigned patients to receive either 325 mg/day of aspirin or warfarin doses calibrated to a pre-specified level of blood thinning. Warfarin therapy requires frequent blood testing to monitor its dosage to achieve the desired level of blood thinning. To avoid bias, all patients had blood drawn on the same schedule and their pills adjusted so neither the patients nor their treating physicians knew which regimen they were taking.

Death, ischemic stroke (caused by blockage of an artery feeding the brain) or intracerebral hemorrhage (bleeding inside the brain), which combined were the study's primary endpoint, occurred at 7.47 percent for patients assigned to warfarin and 7.93 percent for patients assigned to aspirin. The difference was not statistically significant.

However, "in the group of patients followed for more than three years, those on warfarin did better in comparison to the aspirin patients," Homma said.

Over the entire study period, patients receiving warfarin were just over half as likely to develop a stroke, a component of the primary endpoint, as those taking aspirin. The rates of stroke were low, with annual rates of 0.72 percent in patients assigned to warfarin and 1.36 percent for those on aspirin.

Researchers evaluated the safety of the anti-clotting medications by monitoring major bleeding events apart from intracerebral hemorrhage (which was a component of the primary endpoint). Each year, major bleeds occurred in 1.8 percent of patients on warfarin and 0.9 percent of those on aspirin - a statistically significant difference.

"As expected, the overall bleeding rate was higher with warfarin," Homma said. "However, not all bleeds are equal, and the one that patients fear the most - bleeding within the brain (intracerebral hemorrhage) rarely occurred in both groups." It occurred in 0.12 percent per year in the warfarin group and 0.05 percent per year in the aspirin group.

"Given that there is no overall difference between the two treatments and that possible benefit of warfarin does not start until after 4 years of treatment, there is no compelling reason to use warfarin, especially considering the bleeding risk", Homma said. The investigators are analyzing whether certain subgroups of patients benefited more from each treatment.

Statements and Conclusions

Statements and conclusions of study authors that are presented at American Stroke Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and funds specific association programs and events. The association has strict policies to prevent these relationships from influencing science content.

Attribution/Source(s):

This quality-reviewed publication was selected for publishing by the editors of Disabled World due to its significant relevance to the disability community. Originally authored by American Stroke Association, and published on 2012/02/06 (Edit Update: 2022/04/27), the content may have been edited for style, clarity, or brevity. For further details or clarifications, American Stroke Association can be contacted at stroke.org. NOTE: Disabled World does not provide any warranties or endorsements related to this article.

Related Publications

Share This Information To:
𝕏.com Facebook Reddit

Page Information, Citing and Disclaimer

Disabled World is an independent disability community founded in 2004 to provide news and information to people with disabilities, seniors, their family and carers. We'd love for you to follow and connect with us on social media!

Cite This Page (APA): American Stroke Association. (2012, February 6 - Last revised: 2022, April 27). Aspirin and Warfarin Comparison for Heart Failure Treatment. Disabled World. Retrieved July 18, 2024 from www.disabled-world.com/medical/pharmaceutical/aspirin-warfarin.php

Permalink: <a href="https://www.disabled-world.com/medical/pharmaceutical/aspirin-warfarin.php">Aspirin and Warfarin Comparison for Heart Failure Treatment</a>: Comparison of two anti-clotting medications warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.